Du är här

2016-05-13

SciBase: Interim Report

January 1 - March, 2016

The first quarter in figures

· Total net sales amounted to TSEK 1,066 (1,057).
· The loss after tax amounted to TSEK 11,600 (9,179).
· The loss per share amounted to SEK 1.40 (1.84).
· The cash flow from current operations was negative in the amount
of TSEK 11,247 (9,197).

· Significant margin improvement with gross margin increasing to
26.3% in Q1 (2.6% Q1 15).

Important events during the quarter

· SciBase's PMA application was accepted on January 14th as complete
starting the formal evaluation process by the FDA. There has been a
high level of interaction between SciBase and the FDA during and
continuing after the first quarter.

· Continued good growth in key market Germany with total sales up
20% and electrode sales volume up 49%.

· SciBase has signed a distribution agreement for Switzerland with
CDP SWISS AG. The sales and marketing effort of SciBase's melanoma
detection product Nevisense will initially focus on the nearly 400
dermatologists that work in private clinics in Switzerland.

· A change in the Company's board of directors was communicated as
Viktor Dvrota, as a result of his appointment as Head of Investment
at Karolinska Development, has resigned from SciBase's Board of
Directors. Alternate director Andreas Pennervall will take his place.

Important events after the end of the period

· On April 25th, the Annual Report for 2015 was published.

Apr 1
2015 -
Jan 1 Mar 31 Jan 1 - Dec 31
- Mar 2016
31
THE GROUP 2016 2015 Rolling 2015
-12
Net sales, SEK ths 1 066 1 057 4 160 4 151
Gross margin, % 26,3% 2,6% 8,5% 2,5%
Equity/Asset ratio, % 94,4% 73,0% 94,4% 95,1%
Net indebtness, multiple 0,06 0,37 0,06 0,05
Cash equivalents, SEK ths 122 17 122 241 133 736
241 313
Cashflow from operating -11 -9 -48 638 -46 588
activities, SEK ths 247 197
Earnings per share (before -1,40 -1,84 -5,68 -6,01
and after dilution), SEK*
Shareholder's equity per 16,19 4,71 17,34 21,09
share, SEK*
Average number of shares, 8 285 4 985 7 735 6 910
000'*
Number of shares at closing 8 285 4 985 8 285 8 285
of period, 000'*
Share price at end of 23,50 - 23,50 31,00
period, SEK
Average number of employees 18 14 15 14
*Adjusted for in May 2015
performed reversed split,
40:1

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in
Stockholm that has developed a unique point-of-care device for the
accurate detection of malignant melanoma. Its product, Nevisense,
helps doctors to detect malignant melanoma, the most dangerous type
of skin cancer. SciBase was founded by Stig Ollmar, Associate
Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense
is based on substantial research and has achieved excellent results
in the largest clinical study ever conducted on the detection of
malignant melanoma. Nevisense is CE marked in Europe, has TGA
approval in Australia, and is awaiting FDA clearance in the United
States. Nevisense is based on a method called Electrical Impedance
Spectroscopy (EIS), which uses the varying electrical properties of
human tissue to categorize cellular structures and thereby detect
malignancies. SciBase is listed on Nasdaq First North ("SCIB").
Avanza is the certified advisor. Further information is available on
www.scibase.com.

SciBase Holding AB is required to disclose the information provided
herein pursuant to the Securities Markets Act and/or the Financial
Instruments Trading Act. The information was submitted for
publication at 8 am on May 13, 2016.

For further information please contact:

Simon Grant, CEO, tele : 46 72 887 43 99

Michael Colérus, CFO, tele : 46 70 341 34 72

-----------------------------------------------------------
http://news.cision.com/scibase/r/interim-report,c2008407
http://mb.cision.com/Main/12371/2008407/515274.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.